• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

医护人员中针对严重急性呼吸综合征冠状病毒2的免疫球蛋白G抗体:一项来自印度的血清学监测研究

Immunoglobulin-G Antibodies against Severe Acute Respiratory Syndrome - Coronavirus-2 among Health-Care Workers: A Serosurveillance Study from India.

作者信息

Prakash Om, Solanki Bhavin, Sheth Jay, Acharya Hemendra, Acharya Swati, Vinzuda Mital, Patani Hari

机构信息

Ahmedabad Municipal Corporation, Ahmedabad, Gujarat, India.

Department of Community Medicine, AMC MET Medical College, Ahmedabad, Gujarat, India.

出版信息

Int J Appl Basic Med Res. 2022 Jan-Mar;12(1):18-23. doi: 10.4103/ijabmr.ijabmr_516_21. Epub 2022 Jan 31.

DOI:10.4103/ijabmr.ijabmr_516_21
PMID:35265476
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8848555/
Abstract

BACKGROUND

Seropositivity among health-care workers (HCWs) may help in better understanding of the immune response after COVID-19 infection.

OBJECTIVES

To estimate seropositivity among HCWs and to compare available variables with seropositivity to understand the factors affecting seropositivity.

MATERIALS AND METHODS

A serosurveillance among HCWs was carried out using population proportion sampling during the second half of October 2020 in the city of Ahmedabad using the Covid-Kavach (immunoglobulin G [IgG] ELISA Antibody testing kit). Simple proportions and appropriate statistical tests were used as needed.

RESULTS

As on October' 2020, HCWs in Ahmedabad demonstrated a seropositivity of 20.84% (95% confidence interval [CI] 19.00-22.81%). Seropositivity among HCWs was lower than that of the general population (24.20%) which was estimated as part of the same study. Female HCWs had higher seropositivity 22.14% (95% CI 19.74-24.74%) as compared to 18.82% (95% CI 16.06-21.93%) among male HCWs and the difference was statistically not significant ( = 1.66, = 0.097). Age groups with increasing age show increasing trend in the seropositivity among HCWs.

CONCLUSION

As on October 2020, with 20.84% seropositivity among HCWs in Ahmedabad, one in every five HCW already demonstrate IgG antibodies against severe acute respiratory syndrome- coronavirus-2. Further scientific studies on seropositivity and the factors affecting the seropositivity may be carried out to uncover more details of immune reaction after COVID-19 infection.

摘要

背景

医护人员的血清阳性反应可能有助于更好地了解新型冠状病毒肺炎(COVID-19)感染后的免疫反应。

目的

评估医护人员的血清阳性率,并将可用变量与血清阳性率进行比较,以了解影响血清阳性率的因素。

材料与方法

2020年10月下旬,在艾哈迈达巴德市采用人群比例抽样法,使用Covid-Kavach(免疫球蛋白G[IgG]酶联免疫吸附测定抗体检测试剂盒)对医护人员进行血清学监测。根据需要使用简单比例和适当的统计检验。

结果

截至2020年10月,艾哈迈达巴德市的医护人员血清阳性率为20.84%(95%置信区间[CI]19.00-22.81%)。医护人员的血清阳性率低于作为同一研究一部分所估计的普通人群(24.20%)。女性医护人员的血清阳性率较高,为22.14%(95%CI 19.74-24.74%),而男性医护人员为18.82%(95%CI 16.06-21.93%),差异无统计学意义(Z=1.66,P=0.097)。随着年龄增长,医护人员血清阳性率呈上升趋势。

结论

截至2020年10月,艾哈迈达巴德市医护人员的血清阳性率为20.84%,每五名医护人员中就有一人已检测出针对严重急性呼吸综合征冠状病毒2的IgG抗体。可进一步开展关于血清阳性率及影响血清阳性率因素的科学研究,以揭示COVID-19感染后免疫反应的更多细节。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dcef/8848555/e1e0966da266/IJABMR-12-18-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dcef/8848555/8f43f716177c/IJABMR-12-18-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dcef/8848555/0ef8d6b4a7fa/IJABMR-12-18-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dcef/8848555/c0b37316214e/IJABMR-12-18-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dcef/8848555/e1e0966da266/IJABMR-12-18-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dcef/8848555/8f43f716177c/IJABMR-12-18-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dcef/8848555/0ef8d6b4a7fa/IJABMR-12-18-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dcef/8848555/c0b37316214e/IJABMR-12-18-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dcef/8848555/e1e0966da266/IJABMR-12-18-g004.jpg

相似文献

1
Immunoglobulin-G Antibodies against Severe Acute Respiratory Syndrome - Coronavirus-2 among Health-Care Workers: A Serosurveillance Study from India.医护人员中针对严重急性呼吸综合征冠状病毒2的免疫球蛋白G抗体:一项来自印度的血清学监测研究
Int J Appl Basic Med Res. 2022 Jan-Mar;12(1):18-23. doi: 10.4103/ijabmr.ijabmr_516_21. Epub 2022 Jan 31.
2
SARS-CoV2 IgG antibody: Seroprevalence among health care workers.严重急性呼吸综合征冠状病毒2型免疫球蛋白G抗体:医护人员中的血清流行率
Clin Epidemiol Glob Health. 2021 Jul-Sep;11:100766. doi: 10.1016/j.cegh.2021.100766. Epub 2021 May 8.
3
Severe acute respiratory syndrome coronavirus 2 immunoglobulin G antibody: Seroprevalence among contacts of COVID-19 cases.严重急性呼吸综合征冠状病毒 2 免疫球蛋白 G 抗体:COVID-19 病例接触者中的血清流行率。
Indian J Public Health. 2021 Jan-Mar;65(1):5-10. doi: 10.4103/ijph.IJPH_1199_20.
4
COVID-Kavach-Based Seropositivity in the General Population of Ahmedabad: Just Before the Start of the Vaccination for the Elderly in India.印度艾哈迈达巴德普通人群中基于COVID-Kavach的血清阳性率:恰好在印度老年人疫苗接种开始之前。
Cureus. 2022 Mar 1;14(3):e22759. doi: 10.7759/cureus.22759. eCollection 2022 Mar.
5
Seroprevalence of Immunoglobulin-G Antibody Among Confirm Cases of COVID-19.新型冠状病毒肺炎确诊病例中免疫球蛋白G抗体的血清阳性率
Cureus. 2021 Sep 14;13(9):e17956. doi: 10.7759/cureus.17956. eCollection 2021 Sep.
6
Assessing seropositivity for IgG antibodies against SARS-CoV-2 in Ahmedabad city of India: a cross-sectional study.印度艾哈迈达巴德市抗SARS-CoV-2 IgG抗体血清阳性率评估:一项横断面研究。
BMJ Open. 2021 Jan 5;11(1):e044101. doi: 10.1136/bmjopen-2020-044101.
7
Seropositivity of severe acute respiratory syndrome coronavirus 2 infection among healthcare workers of the Armed Forces medical services, India: A multicentric study.印度武装部队医疗服务部门医护人员中严重急性呼吸综合征冠状病毒2感染的血清阳性率:一项多中心研究。
Med J Armed Forces India. 2021 Jul;77(Suppl 2):S359-S365. doi: 10.1016/j.mjafi.2021.03.020. Epub 2021 Jul 26.
8
Characteristics and Immunoglobulin G Seropositivity among COVID-19 Positive Healthcare Workers in a Tertiary Care Hospital in Oman.阿曼一家三级护理医院中新冠病毒检测呈阳性的医护人员的特征及免疫球蛋白G血清阳性情况
Oman Med J. 2021 Sep 30;36(5):e302. doi: 10.5001/omj.2021.116. eCollection 2021 Sep.
9
Population-based seropositivity for IgG antibodies against SARS-CoV-2 in Ahmedabad city.艾哈迈达巴德市人群中针对新冠病毒的IgG抗体血清阳性率
J Family Med Prim Care. 2021 Jun;10(6):2363-2368. doi: 10.4103/jfmpc.jfmpc_2062_20. Epub 2021 Jul 2.
10
Relationship between Acute-Phase Symptoms and Immunoglobulin G Seropositivity up to Eight Months after COVID-19.急性症状与 COVID-19 后 8 个月内免疫球蛋白 G 血清阳性之间的关系。
Medicina (Kaunas). 2022 May 26;58(6):708. doi: 10.3390/medicina58060708.

引用本文的文献

1
COVID-Kavach-Based Seropositivity in the General Population of Ahmedabad: Just Before the Start of the Vaccination for the Elderly in India.印度艾哈迈达巴德普通人群中基于COVID-Kavach的血清阳性率:恰好在印度老年人疫苗接种开始之前。
Cureus. 2022 Mar 1;14(3):e22759. doi: 10.7759/cureus.22759. eCollection 2022 Mar.

本文引用的文献

1
Population-based seropositivity for IgG antibodies against SARS-CoV-2 in Ahmedabad city.艾哈迈达巴德市人群中针对新冠病毒的IgG抗体血清阳性率
J Family Med Prim Care. 2021 Jun;10(6):2363-2368. doi: 10.4103/jfmpc.jfmpc_2062_20. Epub 2021 Jul 2.
2
SARS-CoV2 IgG antibody: Seroprevalence among health care workers.严重急性呼吸综合征冠状病毒2型免疫球蛋白G抗体:医护人员中的血清流行率
Clin Epidemiol Glob Health. 2021 Jul-Sep;11:100766. doi: 10.1016/j.cegh.2021.100766. Epub 2021 May 8.
3
SARS-CoV-2 Seroprevalence Among Healthcare Workers by Workplace Exposure Risk in Kashmir, India.
印度克什米尔地区不同工作场所暴露风险的医护人员中 SARS-CoV-2 血清流行率。
J Hosp Med. 2021 May;16(5):274-281. doi: 10.12788/jhm.3609.
4
Early Viral Clearance and Antibody Kinetics of COVID-19 Among Asymptomatic Carriers.无症状携带者中 COVID-19 的早期病毒清除及抗体动力学
Front Med (Lausanne). 2021 Mar 15;8:595773. doi: 10.3389/fmed.2021.595773. eCollection 2021.
5
Severe acute respiratory syndrome coronavirus 2 immunoglobulin G antibody: Seroprevalence among contacts of COVID-19 cases.严重急性呼吸综合征冠状病毒 2 免疫球蛋白 G 抗体:COVID-19 病例接触者中的血清流行率。
Indian J Public Health. 2021 Jan-Mar;65(1):5-10. doi: 10.4103/ijph.IJPH_1199_20.
6
Assessing seropositivity for IgG antibodies against SARS-CoV-2 in Ahmedabad city of India: a cross-sectional study.印度艾哈迈达巴德市抗SARS-CoV-2 IgG抗体血清阳性率评估:一项横断面研究。
BMJ Open. 2021 Jan 5;11(1):e044101. doi: 10.1136/bmjopen-2020-044101.
7
SARS-CoV-2 seroprevalence worldwide: a systematic review and meta-analysis.全球范围内 SARS-CoV-2 血清流行率:系统评价和荟萃分析。
Clin Microbiol Infect. 2021 Mar;27(3):331-340. doi: 10.1016/j.cmi.2020.10.020. Epub 2020 Oct 24.
8
Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19.新冠病毒感染轻症与重症患者的系统性及黏膜性抗体对 SARS-CoV-2 的应答特征。
J Allergy Clin Immunol. 2021 Feb;147(2):545-557.e9. doi: 10.1016/j.jaci.2020.10.040. Epub 2020 Nov 20.
9
SARS-CoV-2 RNA shedding in recovered COVID-19 cases and the presence of antibodies against SARS-CoV-2 in recovered COVID-19 cases and close contacts, Thailand, April-June 2020.2020 年 4 月至 6 月,泰国新冠肺炎康复病例的 SARS-CoV-2 病毒 RNA 脱落情况,以及新冠肺炎康复病例和密切接触者中针对 SARS-CoV-2 的抗体情况。
PLoS One. 2020 Oct 29;15(10):e0236905. doi: 10.1371/journal.pone.0236905. eCollection 2020.
10
Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans.人类感染 SARS-CoV-2 后三个月内中和抗体反应的纵向观察和下降。
Nat Microbiol. 2020 Dec;5(12):1598-1607. doi: 10.1038/s41564-020-00813-8. Epub 2020 Oct 26.